<DOC>
	<DOCNO>NCT01072747</DOCNO>
	<brief_summary>The primary objective study verify , randomize , blind , parallel clinical trial , efficacy bovine heparin Bergamo Laboratory ACTIPARIN Â® product compare porcine heparin APP Pharmaceutical patient undergo surgery cardiovascular disease require cardiopulmonary bypass , control hemostasis surgery , base measurement marker coagulation ACT , aPTT , anti-Xa heparin level excessive blood loss ( hemorrhage ) end surgery .</brief_summary>
	<brief_title>Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients agree aspect study sign FICT ; Patients sex ; Patients age 18 year ; Patients indication cardiac surgery require cardiopulmonary bypass . Patients hematological disorder compromise surgical outcome ( eg , myeloproliferative disorder , anemia , Hb &lt; 11.0 g / dL , platelet &lt; 100,000 mm3 ) ; Patients disorder hemostasis ( INR &gt; 1.40 ) ( APTTr &gt; 1.40 ) ; Patients renal impairment ( creatinine &gt; 1.50 ) ; Patients deep hyperthermia ; Liver disease ( AST ALT &gt; 2 time reference value ) ; Patients history allergy heparin protamine ; Patients history heparininduced thrombocytopenia ; infection ( eg endocarditis , septicemia pneumonia ) ; Reoperations ; Use antiplatelet agent ( clopidogrel ticlopidine ) less 7 day ; Use aspirin less 5 day ; Use heparin , low molecular weight le 24 hour ; Use unfractionated heparin le 12 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>